Vistagen Therapeutics, INC 8-K filings

Vistagen Therapeutics announced fiscal Q1 FY27 financial results, highlighting revenue from an agreement expiration, reduced operating expenses, and a net loss, alongside mixed clinical data for fasedienol and a cash runway extending into 2027.

Vistagen Therapeutics announced topline results from its exploratory Phase 2 study of fasedienol nasal spray for social anxiety disorder, showing favorable safety and numerical efficacy signals, particularly in a severe subgroup.

Vistagen Therapeutics announces the appointment of Dr. Douglas J. Williamson, a seasoned neuroscience drug development expert, to its Board of Directors.

Vistagen Therapeutics announced topline results from its PALISADE-4 Phase 3 trial for fasedienol, which did not meet its primary endpoint in the overall population but showed a statistically significant effect in a subpopulation with very severe social anxiety disorder.

Vistagen Therapeutics directors Margaret FitzPatrick and Dr. Joanne Curley have announced they will not stand for re-election at the 2026 Annual Meeting.

Vistagen Therapeutics announced fiscal year 2026 financial results, highlighting progress in its late-stage clinical programs for social anxiety disorder, depression, and menopausal hot flashes, with key trial data expected soon.

Vistagen Therapeutics announced that its fasedienol clinical program has met international ICH E1 safety exposure standards for social anxiety disorder treatment.

Vistagen Therapeutics announces preliminary positive data from the open-label extension of its Phase 3 PALISADE-3 study for fasedienol, showing well-tolerated safety and clinically relevant improvements in social anxiety.

Vistagen Therapeutics has completed the randomized portion of its Phase 3 PALISADE-4 clinical trial for fasedienol in social anxiety disorder.

Vistagen Therapeutics announced it has received a Study May Proceed letter from the FDA for refisolone nasal spray, enabling further Phase 2 clinical development for menopausal hot flashes.

Vistagen Therapeutics announced the approval of retention awards in the form of stock options for all employees, including key executives, to incentivize continued service and align interests.

Mary Rotunno has resigned from Vistagen Therapeutics, Inc.'s Board of Directors, effective April 1, 2026.

Vistagen Therapeutics highlights its pherine pipeline, including fasedienol's ongoing Phase 3 program for social anxiety disorder and positive data for other candidates.

Paul Edick has resigned from the Board of Directors of Vistagen Therapeutics, Inc., effective February 13, 2026.

Vistagen Therapeutics announced its fiscal year 2026 third-quarter financial results, alongside updates on its fasedienol Phase 3 trial and refisolone development.

Vistagen Therapeutics, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement for continued listing.

Vistagen Therapeutics, Inc. unveiled a new corporate presentation showcasing its clinical-stage pherine product candidates and nose-to-brain neurocircuitry platform.

Vistagen Therapeutics announced its PALISADE-3 Phase 3 study for intranasal fasedienol in social anxiety disorder did not meet its primary endpoint.

Vistagen Therapeutics strengthens its leadership team with the appointment of Nick Tressler as Chief Financial Officer, effective December 1, 2025.

Vistagen Therapeutics announced its fiscal Q2 2026 financial results and provided an update on its fasedienol Phase 3 clinical trials for social anxiety disorder, with topline data from PALISADE-3 expected by calendar year-end.

Vistagen Therapeutics announced the completion of the public speaking challenge portion of its PALISADE-3 Phase 3 clinical trial for fasedienol in social anxiety disorder, with topline results expected by year-end.

Vistagen Therapeutics strengthens its Board of Directors with the appointment of biopharmaceutical industry veteran Paul R. Edick, who will also serve on the Audit and Compensation Committees.

Vistagen Therapeutics announces its CFO's resignation and the results of its 2025 Annual Meeting, where directors were elected, executive compensation approved, and auditors ratified.

Vistagen Therapeutics reports fiscal year 2026 first quarter financial results and provides a corporate update, highlighting progress in its intranasal pherine pipeline with key clinical trial milestones anticipated.

Vistagen Therapeutics, a late clinical-stage biopharmaceutical company, announced the appointment of Elissa Cote as Chief Corporate Development Officer, effective June 23, 2025, to lead strategic opportunities and partnerships for its novel neuroscience pipeline.

Vistagen Therapeutics announced its fiscal year 2025 financial results, reporting a significant increase in net loss and expenses, alongside progress in its clinical pipeline and the filing of a prospectus supplement to raise up to $175 million through an at-the-market offering.

Vistagen Therapeutics, Inc. announced updated timelines for its fasedienol PALISADE Phase 3 Program for social anxiety disorder, with PALISADE-3 on track for Q4 2025 data and PALISADE-4 now expected in 1H 2026 due to strategic enhancements.

Vistagen Therapeutics presents at the TD Cowen Healthcare Conference, announces participation in the Stifel CNS Forum, and faces a securities lawsuit alleging misleading statements regarding clinical trials.

Vistagen Therapeutics reports its fiscal year 2025 third quarter financial results, highlighting the progress of its PALISADE Phase 3 Program for social anxiety disorder and its clinical-stage pipeline of pherine product candidates.

Vistagen Therapeutics has been granted a U.S. patent for its non-opioid product candidate, AV-101, for the treatment of neuropathic pain, extending patent protection to at least 2034.